Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: RWReeves who wrote (900)	3/31/2000 7:42:00 AM
From: Jim Oravetz	Read Replies (1) \| Respond to of 52153

<at new, lower prices> Sounds like the WalMart slogan! While there are "others", one bio issue that seems to have weathered the downdraft is Forest Lab's (FRX). Even with a recent downgrade, the stock has barely moved south. A quick check of the profile: siliconinvestor.com 87% held by institutions Good ROE Current Ratio > 3.84 x10 Book The prime sales driver is: Celexa, a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of depression. Of course, with the market retracting the way it has been, sales of this product can only go up! The only negitive is that the chances for a x10 are low at these prices (~$80/sh). Where is the FRX thread? Jim